What are the recommended starting doses and titration schedule for brexpiprazole (Rexulti) for schizophrenia and major depressive disorder?

Rexulti (Brexpiprazole) Starting Doses and Titration

For major depressive disorder (MDD), start Rexulti at 0.5 mg or 1 mg once daily, titrate to 1 mg daily, then increase to the target dose of 2 mg daily at weekly intervals, with a maximum of 3 mg daily; for schizophrenia in adults, start at 1 mg daily for days 1-4, increase to 2 mg on days 5-7, then may increase to 4 mg on day 8 based on response. 1

Major Depressive Disorder (Adjunctive Treatment) - Adults

Starting and Titration:

• Start: 0.5 mg OR 1 mg once daily
• Week 1: Titrate to 1 mg once daily
• Target dose: 2 mg once daily (increase at weekly intervals based on clinical response and tolerability)
• Maximum: 3 mg once daily 1

The target dose of 2 mg daily is supported by pooled trial data showing 23.2% response rate versus 14.5% for placebo (NNT = 12) 2. Recent evidence demonstrates efficacy regardless of whether patients show minimal or partial response to antidepressant monotherapy 3.

Schizophrenia - Adults

Starting and Titration:

• Days 1-4: 1 mg once daily
• Days 5-7: 2 mg once daily
• Day 8 onward: May increase to 4 mg once daily based on clinical response and tolerability
• Target dose: 2-4 mg once daily
• Maximum: 4 mg once daily 1

This dosing achieves a 45.5% response rate versus 31.0% for placebo (NNT = 7) in acute schizophrenia 2. The 2025 INTEGRATE guidelines note that brexpiprazole, as a D2 partial agonist, may be considered as first-line treatment, with switching to alternative agents if inadequate response after 4 weeks at therapeutic dose 4.

Schizophrenia - Pediatric Patients (Ages 13-17)

Starting and Titration:

• Days 1-4: 0.5 mg once daily
• Days 5-7: 1 mg once daily
• Day 8: 2 mg once daily
• Subsequent increases: 1 mg increments weekly as needed
• Target dose: 2-4 mg once daily
• Maximum: 4 mg once daily 1

This pediatric dosing was approved using PK bridging from adult data, demonstrating comparable exposures between age groups 5.

Agitation Associated with Dementia Due to Alzheimer's Disease

Starting and Titration:

• Days 1-7: 0.5 mg once daily
• Days 8-14: 1 mg once daily
• Day 15: 2 mg once daily
• Target dose: 2 mg once daily
• Maximum: 3 mg once daily (may increase after at least 14 days at 2 mg based on response) 1

Critical Dose Adjustments

Hepatic Impairment (Child-Pugh Score ≥7)

• MDD or Alzheimer's agitation: Maximum 2 mg once daily
• Schizophrenia: Maximum 3 mg once daily 1

Renal Impairment (CrCl <60 mL/min)

• MDD or Alzheimer's agitation: Maximum 2 mg once daily
• Schizophrenia: Maximum 3 mg once daily 1

CYP2D6 Poor Metabolizers or Drug Interactions

Reduce dose by 50% when:

• Patient is known CYP2D6 poor metabolizer
• Taking strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin)
• Taking strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine, quinidine)

Reduce dose by 25% when taking moderate-to-strong CYP2D6 inhibitor PLUS moderate-to-strong CYP3A4 inhibitor

Double the usual dose when taking strong CYP3A4 inducers (e.g., rifampin, carbamazepine); taper back to original dose over 1-2 weeks when inducer is discontinued 1

Important caveat: PBPK modeling suggests the 50% dose reduction in CYP2D6 poor metabolizers may overcompensate, potentially delaying time to effective concentrations 6. However, follow FDA labeling until further clinical data emerge.

Administration Details

• Timing: Once daily, with or without food 1
• Assessment: Evaluate treatment effectiveness early; allow at least 4 weeks at therapeutic dose before switching in schizophrenia per INTEGRATE guidelines 4
• Reassessment: Periodically reassess continued need and appropriate dosage, particularly in MDD 1

Common Pitfalls to Avoid

1. Titrating too rapidly: Weekly intervals are recommended for MDD; specific day-by-day schedules for schizophrenia must be followed to minimize akathisia risk (NNH = 15 in MDD) 2

2. Ignoring drug interactions: Failure to adjust for CYP2D6/3A4 inhibitors or inducers can lead to excessive exposure or therapeutic failure 1

3. Overlooking renal/hepatic function: These require mandatory dose caps that differ by indication 1

4. Premature discontinuation: Weight gain (NNH = 17 for ≥7% increase) is modest short-term but more prominent in long-term studies; proactive metabolic monitoring is essential 2